Breaking News Instant updates and real-time market news.

AAPL

Apple

$188.51

-2.6 (-1.36%)

, SNE

Sony

$42.00

-0.09 (-0.21%)

14:03
03/25/19
03/25
14:03
03/25/19
14:03

Apple bringing Apple TV app to Samsung, LG, Sony, Vizio smart televisions

AAPL

Apple

$188.51

-2.6 (-1.36%)

SNE

Sony

$42.00

-0.09 (-0.21%)

  • 25

    Mar

  • 03

    Jun

AAPL Apple
$188.51

-2.6 (-1.36%)

03/21/19
RHCO
03/21/19
NO CHANGE
RHCO
Apple event may be negative for Netflix, positive for Lions Gate, says SunTrust
SunTrust analyst Matthew Thornton previews Apple's (AAPL) media event scheduled for March 25th, saying the company is likely to unveil a Video Service. The analyst believes that an Apple OTT service could be a positive for Lions Gate (LGF.B) given the participation of the Starz networks but negative for Netflix (NFLX) "if Apple can offer compelling content bundles at compelling prices with a compelling UI and ubiquitous access". Thornton adds that Apple's bundling of its Music with video subscriptions and news subscriptions may be a negative for Spotify (SPOT) and a "modest incremental negative" for Roku (ROKU) if Apple's service app is not on its service.
03/22/19
JPMS
03/22/19
UPGRADE
Target $65
JPMS
Overweight
JPMorgan upgrades Lumentum to Overweight on iPhone volume stabilization
JPMorgan analyst Samik Chatterjee upgraded Lumentum Holdings (LITE) to Overweight from Neutral and raised his price target for the shares to $65 from $50. The stock closed yesterday up $2.44, of 5%, to $52.10. The analyst sees a "solid" outlook for the company's telecom business amid "strong" growth led by 5G investments and upside to synergy targets relative to recent acquisition of Oclaro. Further, he sees limited downside risk relative to volume expectations for Apple's (AAPL) iPhone, which he notes has been a "key driver of sentiment on the shares." Stabilization of its iPhone volume outlook should drive focus back to the "strong" fundamentals in Lumentum's primary telecom business, Chatterjee tells investors in a research note.
03/22/19
MSCO
03/22/19
NO CHANGE
MSCO
Overweight
Apple streaming service timing, robustness key details, says Morgan Stanley
Morgan Stanley analyst Katy Huberty said she expects next Monday's special event from Apple to be focused on new Services launches, specifically a streaming video on demand service and likely a paid subscription news and magazine service. Huberty believes that besides the launch of an Apple Media bundle, which she would view as the most bullish potential announcement, the inclusion of video content from other programmers would be a positive and the launch timing and robustness of the offerings are the most important details to watch. A meaningful delay in the launch of original video content could hamper customer adoption and pricing at or above market for a stand-alone streaming video service could also slow adoption, said Huberty, who has an Overweight rating on Apple shares.
03/25/19
BTIG
03/25/19
NO CHANGE
Target $220
BTIG
Buy
Apple price target raised to $220 from $189 at BTIG
BTIG analyst Walter Piecyk raised his price target on Apple to $220 and kept his Buy rating ahead of its product event today, saying that while the rally of the stock price could stall, his new target assumes the company will return to growth in 2020. The analyst notes that while the recent data points have not been positive for Apple's iPhone business expectations, he continues to expect abating lengthening of the product cycle to materialize in 2020. Piecyk adds that stock buybacks and the company's capital program should be the primary driver Apple's earnings growth.
SNE Sony
$42.00

-0.09 (-0.21%)

03/20/19
JEFF
03/20/19
DOWNGRADE
Target $50.7
JEFF
Hold
Sony downgraded to Hold from Buy at Jefferies
Jefferies analyst Atul Goyal downgraded Sony to Hold from Buy and lowered his price target for the shares to $50.70 from $77.62.
03/20/19
KEYB
03/20/19
NO CHANGE
KEYB
Google's Stadia announcement potentially disruptive, says KeyBanc
KeyBanc analyst Evan Wingren attended Google's (GOOG; GOOGL) keynote at Game Developer's Conference, where it announced a new video game streaming service, new gaming hardware, and intentions to make games. The analyst believes the announcement has potential to be disruptive if Google executes well on the service, and sees it as mostly positive for video game publishers in the near and long term as it increases global access, removes value added by hardware, and increases value of key content. Google's ambitions to make games join other distributors like Sony (SNE), Microsoft (MSFT), and Amazon (AMZN), and could provide some incremental competition for time in the medium to long term, Wingren contends.
03/20/19
JEFF
03/20/19
DOWNGRADE
Target $50.7
JEFF
Hold
Jefferies downgrades Sony on lower growth, increasing uncertainty
Jefferies analyst Atul Goyal downgraded Sony to Hold from Buy and lowered his price target for the shares to $50.70 from $77.62. Sony's inability to exit the Smartphone business has resulted in continued losses while a peak of game profits and increasing uncertainty imply "pedestrian profit growth" over the next two years, Goyal tells investors in a research note. He believes the stock's upside/downside ratio appears balanced at current levels.
03/20/19
BUCK
03/20/19
NO CHANGE
BUCK
Buckingham Neutral on Electronic Arts, but remains opportunistic on weakness
Buckingham analyst Matthew Harrigan maintained a Neutral rating on Electronic Arts with a $103 price target. The analyst said, however, that he remains "opportunistic on any weakness during market sell-offs" due to Google's (GOOG, GOOGL) Stadia initiative. Harrigan said that EA will be "wary of the economics that Google is likely to extend in any sharing model" and noted that EA has to be mindful of existing console partners Microsoft (MSFT) and Sony (SNE).

TODAY'S FREE FLY STORIES

IFF

International Flavors

$142.03

0.21 (0.15%)

, DD

DuPont

$63.60

1.6 (2.58%)

13:47
12/08/19
12/08
13:47
12/08/19
13:47
Periodicals
International Flavors in talks to buy DuPont nutrition unit, Bloomberg reports »

International Flavors…

IFF

International Flavors

$142.03

0.21 (0.15%)

DD

DuPont

$63.60

1.6 (2.58%)

KRYAY

Kerry Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWRF

China Tower

$0.00

(0.00%)

13:40
12/08/19
12/08
13:40
12/08/19
13:40
Upgrade
China Tower rating change  »

China Tower upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

13:37
12/08/19
12/08
13:37
12/08/19
13:37
Recommendations
Principia Biopharma analyst commentary  »

Principia shares have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$50.93

0.495 (0.98%)

12:48
12/08/19
12/08
12:48
12/08/19
12:48
Syndicate
Dycom withdraws senior notes offering due to market conditions »

Dycom Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

IMV

IMV Inc.

$2.92

0.07 (2.46%)

12:30
12/08/19
12/08
12:30
12/08/19
12:30
Hot Stocks
IMV announces updated results from Phase 2 study of DPX-Survivac »

IMV Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KURA

Kura Oncology

$15.67

0.48 (3.16%)

12:27
12/08/19
12/08
12:27
12/08/19
12:27
Hot Stocks
Kura Oncology announces updates for lead drug candidate tipifarnib »

Kura Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PTLA

Portola Pharmaceuticals

$29.22

0.86 (3.03%)

12:24
12/08/19
12/08
12:24
12/08/19
12:24
Hot Stocks
Portola presents interim results from Phase 2a study of cerdulatinib »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

11:25
12/08/19
12/08
11:25
12/08/19
11:25
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

10:49
12/08/19
12/08
10:49
12/08/19
10:49
Hot Stocks
Fate Therapeutics announces vivo preclinical data for FT596 »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

09:22
12/08/19
12/08
09:22
12/08/19
09:22
Hot Stocks
Agios says proof-of-concept has been established for mitapivat »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ZIOP

Ziopharm

$5.16

0.06 (1.18%)

09:20
12/08/19
12/08
09:20
12/08/19
09:20
Hot Stocks
Ziopharm reports pre-clinical data of Rapid Personalized Manufacture »

Ziopharm Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGTX

TG Therapeutics

$7.11

-0.57 (-7.42%)

09:18
12/08/19
12/08
09:18
12/08/19
09:18
Hot Stocks
TG Therapeutics reports triple therapy data from Phase I/II study of ublitux »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:16
12/08/19
12/08
09:16
12/08/19
09:16
Hot Stocks
Karyopharm says four posters will be presented at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPHA

Innate Pharma

$6.30

(0.00%)

09:13
12/08/19
12/08
09:13
12/08/19
09:13
Hot Stocks
Innate Pharma reports long-term data from Phase III trial of Lumoxiti »

Innate Pharma shared new,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.26

4.02 (1.09%)

09:11
12/08/19
12/08
09:11
12/08/19
09:11
Hot Stocks
Regeneron reports initial data for REGN5458 in myeloma patients »

Regeneron Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:09
12/08/19
12/08
09:09
12/08/19
09:09
Hot Stocks
Blueprint reports 77% overall response rate in 48 patients from Explorer trial »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:06
12/08/19
12/08
09:06
12/08/19
09:06
Hot Stocks
Blueprint announces initial data from Phase 2 Pioneer trial in mastocytosis »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.